# Selective CD28 Blockade in Renal Transplant Recipients

> **NCT04903054** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Kidney Transplantation
- Renal Transplant Recipients

## Interventions

- **BIOLOGICAL:** Lulizumab
- **DRUG:** Tacrolimus
- **BIOLOGICAL:** Thymoglobulin®
- **DRUG:** Methylprednisolone
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04903054
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-10
- **Primary completion:** 2022-09-22
- **Final completion:** 2022-09-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Limited period of availability of a supply of the study drug and difficulties in enrollment
- **Last updated:** 2023-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903054, "Selective CD28 Blockade in Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04903054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*